MX2017010348A - Compuestos de amida como agonistas del receptor de la 5-hidroxitriptamina 4 (5-ht4). - Google Patents
Compuestos de amida como agonistas del receptor de la 5-hidroxitriptamina 4 (5-ht4).Info
- Publication number
- MX2017010348A MX2017010348A MX2017010348A MX2017010348A MX2017010348A MX 2017010348 A MX2017010348 A MX 2017010348A MX 2017010348 A MX2017010348 A MX 2017010348A MX 2017010348 A MX2017010348 A MX 2017010348A MX 2017010348 A MX2017010348 A MX 2017010348A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- receptor agonists
- amide compounds
- relates
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente invención se relaciona con compuestos de la fórmula (I), incluyendo sus estereoisómeros y sales farmacéuticamente aceptables. Esta invención también se relaciona con métodos para hacer tales compuestos y con las composiciones farmacéuticas que comprenden tales compuestos. Los compuestos de esta invención son útiles en el tratamiento de varios trastornos que están relacionados con el receptor de la 5-hidroxitriptamina 4 (5-HT4). (ver Fórmula).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN709CH2015 | 2015-02-13 | ||
PCT/IN2016/000008 WO2016128990A1 (en) | 2015-02-13 | 2016-01-07 | Amide compounds as 5-ht4 receptor agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2017010348A true MX2017010348A (es) | 2018-06-07 |
MX368214B MX368214B (es) | 2019-09-24 |
Family
ID=55588327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017010348A MX368214B (es) | 2015-02-13 | 2016-01-07 | Compuestos de amida como agonistas del receptor de la 5-hidroxitriptamina 4 (5-ht4). |
Country Status (29)
Country | Link |
---|---|
US (1) | US9957257B2 (es) |
EP (1) | EP3265459B1 (es) |
JP (1) | JP6487564B2 (es) |
KR (1) | KR101966576B1 (es) |
CN (1) | CN107406434B (es) |
AU (1) | AU2016217461B2 (es) |
BR (1) | BR112017017275A2 (es) |
CA (1) | CA2975973C (es) |
CY (1) | CY1121898T1 (es) |
DK (1) | DK3265459T3 (es) |
EA (1) | EA034618B1 (es) |
ES (1) | ES2734734T3 (es) |
HR (1) | HRP20191179T1 (es) |
HU (1) | HUE045667T2 (es) |
IL (1) | IL253848B (es) |
LT (1) | LT3265459T (es) |
MA (1) | MA41633B1 (es) |
MD (1) | MD3265459T2 (es) |
ME (1) | ME03430B (es) |
MX (1) | MX368214B (es) |
NZ (1) | NZ734400A (es) |
PL (1) | PL3265459T3 (es) |
PT (1) | PT3265459T (es) |
RS (1) | RS59066B1 (es) |
SG (1) | SG11201706501VA (es) |
SI (1) | SI3265459T1 (es) |
TR (1) | TR201909997T4 (es) |
WO (1) | WO2016128990A1 (es) |
ZA (1) | ZA201705292B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE033114T2 (en) | 2011-11-18 | 2017-11-28 | Heptares Therapeutics Ltd | Muscarin M1 receptor agonists |
GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
GB201709652D0 (en) * | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
CN110818661B (zh) * | 2019-12-02 | 2021-08-06 | 上海再启生物技术有限公司 | 5-ht4受体激动剂的关键中间体4-氨基-5-卤苯并呋喃-7-羧酸的制备方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0416813A (pt) | 2003-11-24 | 2007-03-06 | Pfizer | compostos de ácido quinolonacarboxìlico com atividade agonista do receptor 5-ht4 |
WO2005092882A1 (en) * | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
ES2523459T3 (es) | 2005-02-25 | 2014-11-26 | Raqualia Pharma Inc | Derivados de benzisoxazol |
WO2007010390A1 (en) | 2005-07-22 | 2007-01-25 | Pfizer Japan Inc. | Indazolecarboxamide derivatives as 5ht4 receptor agonists |
WO2007048643A1 (en) * | 2005-10-28 | 2007-05-03 | Glaxo Group Limited | Novel compound |
GB0525661D0 (en) * | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Novel compounds |
GB0603550D0 (en) * | 2006-02-22 | 2006-04-05 | Glaxo Group Ltd | Novel compounds |
US8980922B2 (en) * | 2010-02-12 | 2015-03-17 | Raqualia Pharma Inc. | 5-HT4 receptor agonists for the treatment of dementia |
SG183111A1 (en) | 2010-02-16 | 2012-09-27 | Pfizer | (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors |
CA2823548C (en) * | 2011-09-19 | 2015-10-27 | Suven Life Sciences Limited | Heteroaryl compounds as 5-ht4 receptor ligands |
CA2907620C (en) * | 2013-03-20 | 2018-03-13 | Suven Life Sciences Limited | 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists |
US9951045B2 (en) | 2013-12-16 | 2018-04-24 | Suven Life Sciences Limited | Indazole compounds as 5-HT4 receptor agonists |
-
2016
- 2016-01-07 MX MX2017010348A patent/MX368214B/es active IP Right Grant
- 2016-01-07 BR BR112017017275A patent/BR112017017275A2/pt not_active IP Right Cessation
- 2016-01-07 TR TR2019/09997T patent/TR201909997T4/tr unknown
- 2016-01-07 CN CN201680015614.4A patent/CN107406434B/zh not_active Expired - Fee Related
- 2016-01-07 AU AU2016217461A patent/AU2016217461B2/en not_active Ceased
- 2016-01-07 HU HUE16711355A patent/HUE045667T2/hu unknown
- 2016-01-07 ES ES16711355T patent/ES2734734T3/es active Active
- 2016-01-07 EA EA201791829A patent/EA034618B1/ru unknown
- 2016-01-07 NZ NZ734400A patent/NZ734400A/en not_active IP Right Cessation
- 2016-01-07 DK DK16711355.4T patent/DK3265459T3/da active
- 2016-01-07 EP EP16711355.4A patent/EP3265459B1/en active Active
- 2016-01-07 SG SG11201706501VA patent/SG11201706501VA/en unknown
- 2016-01-07 CA CA2975973A patent/CA2975973C/en not_active Expired - Fee Related
- 2016-01-07 ME MEP-2019-190A patent/ME03430B/me unknown
- 2016-01-07 PT PT16711355T patent/PT3265459T/pt unknown
- 2016-01-07 US US15/549,663 patent/US9957257B2/en active Active
- 2016-01-07 RS RS20190836A patent/RS59066B1/sr unknown
- 2016-01-07 PL PL16711355T patent/PL3265459T3/pl unknown
- 2016-01-07 MD MDE20180052T patent/MD3265459T2/ro not_active IP Right Cessation
- 2016-01-07 MA MA41633A patent/MA41633B1/fr unknown
- 2016-01-07 WO PCT/IN2016/000008 patent/WO2016128990A1/en active Application Filing
- 2016-01-07 SI SI201630311T patent/SI3265459T1/sl unknown
- 2016-01-07 KR KR1020177025584A patent/KR101966576B1/ko active IP Right Grant
- 2016-01-07 LT LTEP16711355.4T patent/LT3265459T/lt unknown
- 2016-01-07 JP JP2017542107A patent/JP6487564B2/ja not_active Expired - Fee Related
-
2017
- 2017-08-04 ZA ZA2017/05292A patent/ZA201705292B/en unknown
- 2017-08-06 IL IL253848A patent/IL253848B/en active IP Right Grant
-
2019
- 2019-07-01 HR HRP20191179TT patent/HRP20191179T1/hr unknown
- 2019-07-10 CY CY20191100739T patent/CY1121898T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
SA518391624B1 (ar) | Ror- منظمات جاما | |
NZ734400A (en) | Amide compounds as 5-ht4 receptor agonists | |
PH12016501440A1 (en) | Novel heterocyclic compounds | |
MX2016017030A (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos. | |
MX2016011632A (es) | Derivados de azaspiro como antagonistas de trpm8. | |
MD4800C1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
MX2020010674A (es) | Agonistas del receptor muscarinico. | |
TN2016000529A1 (en) | Substituted dihydroisoquinolinone compounds | |
PH12017500821A1 (en) | Morpholine and 1, 4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists | |
EA201700042A1 (ru) | Соединения имидазопиридазина | |
EA201692260A1 (ru) | Соединения 1,3,4-тиадиазола и их применение в лечении рака | |
NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
NZ740587A (en) | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators | |
MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
NZ720879A (en) | Indazole compounds as 5-ht4 receptor agonists | |
PH12017501736A1 (en) | Indole derivatives | |
PH12017501134A1 (en) | Fumagillol derivatives | |
EA202090397A1 (ru) | Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht-рецептора | |
WO2014147636A8 (en) | 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists | |
MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |